C
0HS8
vs
S&P 500
S&P 500
Over the past 12 months, 0HS8 has underperformed S&P 500, delivering a return of -24% compared to the S&P 500's +13% growth.
Stocks Performance
0HS8 vs S&P 500
Performance Gap
0HS8 vs S&P 500
Performance By Year
0HS8 vs S&P 500
Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.
Caladrius Biosciences Inc
Glance View
Caladrius Biosciences, Inc. is a biopharmaceutical company, which engages in development of cell therapies for select cardiovascular and autoimmune diseases. The company is headquartered in Basking Ridge, New Jersey and currently employs 27 full-time employees. The firm is developing therapeutics based on the characteristics of naturally occurring CD34+ cells and their ability to stimulate the growth of new microvasculature. The Company’s product candidates include CLBS16, CLBS12 and CLBS201. The CLBS16 (XOWNA) is an experimental regenerative medicine that is being studied in a Phase IIb study (the FREEDOM trial) in the United States for the treatment of coronary microvascular dysfunction. The CLBS12 (HONEDRA) is an experimental regenerative medicine being studied in Japan for the prevention of serious adverse consequences of critical limb ischemia. The CLBS201 is an experimental regenerative medicine designed to assess the safety and efficacy of CD34+ cell therapy as a treatment for diabetic kidney disease.